Hisamitsu Pharmaceutical Co Inc
Stock Price Chart
2026/05/11 UpdatedPrice Trend
2026/05/11 UpdatedPrice & Trading Details
2026/05/11 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/06/05Earnings Calendar
Updated 2026/06/05Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2025/07/09 | ¥68.80 | ¥35.14 | -48.9% |
| 2024/07/11 | ¥43.60 | ¥63.89 | +46.5% |
| 2023/07/13 | ¥19.40 | ¥52.09 | +168.5% |
| 2022/07/07 | ¥22.20 | ¥20.46 | -7.8% |
Shareholder Composition
Updated 2026/06/05Major Holders
Updated 2026/06/05| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
750.7K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
484.6K | +2.56% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
175.3K | +26.12% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.
|
165.9K | +6.14% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
133.6K | 0.00% | |
|
VANGUARD WHITEHALL Fd.S-Vanguard Intl Dividend Appreciation Index Fd.
|
124.9K | -2.50% |
Dividend History 4Years Growth
Updated 2026/06/04| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥105 | +20.0% |
| 2024 | ¥88 | +3.2% |
| 2023 | ¥85 | +0.6% |
| 2022 | ¥84 | +0.6% |
| 2021 | ¥84 | - |
Financial Performance
2026/06/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥120,193M | ¥128,330M | ¥141,706M | ¥156,006M |
| Gross Profit | ¥70,067M | ¥72,699M | ¥78,970M | ¥91,196M |
| Operating Income | ¥9,337M | ¥11,600M | ¥13,167M | ¥18,896M |
| Pretax Income | ¥12,976M | ¥16,128M | ¥19,204M | ¥28,710M |
| Net Income | ¥9,658M | ¥11,742M | ¥13,969M | ¥21,758M |
| EPS | ¥118.84 | ¥147.88 | ¥181.42 | ¥295.57 |
| Operating Margin | 7.77% | 9.04% | 9.29% | 12.11% |
| Balance Sheet | ||||
| Total Assets | ¥302,858M | ¥313,917M | ¥328,779M | ¥343,068M |
| Total Equity | ¥253,165M | ¥256,362M | ¥264,871M | ¥276,822M |
| Total Liabilities | ¥49,693M | ¥57,555M | ¥63,908M | ¥66,246M |
| Cash | ¥129,290M | ¥122,154M | ¥112,459M | ¥114,518M |
| Interest-bearing Debt | ¥2,460M | ¥2,295M | ¥2,100M | ¥3,856M |
| Equity Ratio | 83.59% | 81.67% | 80.56% | 80.69% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥19,199M | ¥12,727M | ¥18,188M | ¥18,765M |
| Investing CF | -¥13,060M | -¥23,868M | -¥2,512M | ¥17,563M |
| Financing CF | -¥15,189M | -¥14,687M | -¥16,691M | -¥15,850M |
| Free CF | ¥15,006M | ¥4,819M | ¥5,152M | ¥4,991M |
| Efficiency | ||||
| ROE | 3.81% | 4.58% | 5.27% | 7.86% |
| ROA | 3.19% | 3.74% | 4.25% | 6.34% |
Latest IR Information
-
[Hisamitsu Pharmaceutical] Notice of Delisting Due to Share Consolidation | May 2026
Hisamitsu Pharmaceutical announced that it approved the share consolidation at an extraordinary general meeting of shareholders held on April 17, 2026, and will delist from the Tokyo, Nagoya, and Fukuoka Stock Exchanges on May 11, 2026. For details, please refer...
Read more -
Notice Regarding Approval Resolution on Share Consolidation, Abolition of Unit Share System, and Partial Amendments to the Articles of Incorporation
Hisamitsu Pharmaceutical will implement a share consolidation on May 13, 2026, reducing the number of issued shares from 70,401,547 shares to 3 shares. Delisting is scheduled for May 11, 2026.
Read more -
Consolidated Financial Summary for the Fiscal Year Ending February 2026 (Japanese GAAP)
For the fiscal year ending February 2026, consolidated net sales were JPY 163.024 billion (an increase of 4.5% YoY), operating income was JPY 17.917 billion (a decrease of 5.2% YoY), and net income attributable to owners of parent was JPY...
Read more -
Executive Personnel Changes
For the Annual General Meeting of Shareholders to be held in May 2026, 10 director candidates have been nominated. One new director and one resigning director have been decided.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥4,300
Rating Score: 3.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.
